The peripheral primitive neuroectodermal tumor (pPNET) is a rare malignant tumor originating from neuroectoderm that usually occurs in children or adolescent and is frequently located in the extremities, chest cavity, pelvic cavity and chest wall. We present a rare case of an 84-year-old man with a history of pPNET in the scrotal sac, to our knowledge not previously published in the literature. The presence of a large irreducible mass in the inguinal sac forced to exclude a tumor. Ultrasound and MRI are very useful modalities to assess the location of the mass, its dependency from any organ and the tumoral internal structure. Molecular imaging with the detection of EWS-FLI1 fusion transcripts is useful for the diagnosis and differential diagnosis of Ewing sarcoma/pPNETs.

Primitive neuroectodermal tumor (PNET) is a rare malignant tumor originating from neuroectoderm. It consists of primitive undifferentiated small round cells and can be divided into central PNET (cPNET) and peripheral PNET (pPNET) tumors based on the tissue of origin. The incidence of pPNET is low, accounting for only about 4% of all soft tissue tumors [1]. The accurate diagnosis is essential for the treatment of pPNET. However, due to their rarity, the radiologic diagnosis of pPNET can be challenging and molecular imaging is the clue for the final diagnosis.

An 84-year-old man was admitted to our hospital with an inguinoscrotal, hard consistency, irreducible, and painless mass, which had progressed over the last 6 months. There was no presence of urinary or intestinal symptoms. Alpha-fetoprotein, beta human chorionic gonadotropin and lactate dehydrogenase values were found normal. Plain abdominal X-ray showed a normal gas pattern. Ultrasound revealed a large mass that occupied the scrotal sac without correctly identification of the testes, thus a magnetic resonance imaging was performed. It confirmed a 12 × 11 × 19 cm solid mass, with areas of necrosis and hemorrhage (fig. 1A). The testes showed a normal morphology and signal on T2-weighted sequences (fig. 1A). Based on these observations, the diagnosis of sarcoma was suggested.

The patient was operated (fig. 1B) and the pathologic (fig. 1C) report with the immunohistochemical stains revealed a rare presentation of a pPNET. The presence of neurosecretory granules in the electronic microscopy and the EWS-FLI1 translocation confirmed the diagnosis (fig. 2). Oncology and urology services decided to submit the patient to radiation therapy and performed a control CT in 6 months, which ruled out tumor recurrence.

Inguinal masses may indicate different conditions and pathologies, ranging from congenital anomalies to neoplasms. Although inguinal hernias represent the majority “masses” in the inguinal canal, there are other rare lesions that may occur. For this reason, irreducible masses shall always receive an appropriate preoperative diagnosis. In this report, we describe a rare case of sarcoma/ pPNET originating from the scrotal sac/inguinal canal in an adult patient.

pPNET is a highly malignant tumor and has poor prognosis. It's an aggressive neoplasm, with a large size at presentation, which metastasize rapidly and predominantly affects children and adolescents [2,3,4]. The most frequent sites for pPNET are the soft tissues or bones of the chest, trunk, pelvis and paraspinal region; they occur less frequently at various other sites along the genitourinary tract, in the testes, the ovaries, the uterus and the pancreas. It is extremely rare in adults but some reports of genitourinary involvement have been described [2,3].

PNET tumor shows no specific imaging features, but radiologic studies are useful to rule out other possible etiologies, defining the location of the tumor and its morphological characteristics as well as its distance extension. A recent article published by Tan et al. [5] reviewed their characteristics on imaging. These tumors were large soft tissue masses (the average diameter was 8.1 cm) with ill-defined margins and exhibited aggressive local extension into normal tissue. On unenhanced CT without contrast the tumors were iso-density and had areas of necrosis. On MRI the tumors were heterogenous hyper-intensity signal on T2. The presence of calcifications are uncommon occurring in less than 10% of tumors. A unique characteristics of pPNET was that most had heterogeneous enhancement, on CT and on MRI had significant enhancement.

Radical surgery is mandatory. On pathology examination, PNET is usually presented as a big grayish-white tumor with multiples areas of necrosis and hemorrhage [1,7]. Calcifications are rare and sometimes it is surrounded by a fibrous capsule [1], as in our case. Histological study consists of small, round to ovoid hyperchromatic cells with minimal cytoplasm and the cells are often arranged in nests forming rosettes. This characteristic is more typical of Ewing sarcoma. In the adult the PNET couldn't have this morphology because it is undifferentiated. All the tumors of the Ewing family are characterized by the staining of MIC2 (CD99) despite the fact that it's not pathognomonic because it is also found in synovial sarcomas and gastrointestinal stromal tumors [1,8]. In order to diagnose PNET, and differentiate it from other tumors of Ewing's family, we need to demonstrate the expression of some neural markers on the inmunohistochemical stains, including neurofilament, NSE (95%), Leu-7, vimentin, S-100, CD-56, chromogranin and synaptophysin [2]. A definitive finding is the EWS-FLI1 translocation, which is described in 95% but its presence is not mandatory for the diagnosis [7,9]. Electron microscopy also displays the neural differentiation because neurosecretory granules could be found.

Comprehensive therapy may include surgery, chemotherapy and radiotherapy. There is no consensus about the treatment of these tumors because there are few cases reported in the literature. For this same reason, it's also difficult to make an inference of stage progression based on the tumor size or site [2]. The best treatment option is to perform an appropriate preoperative work-up in order to plan the surgery [3]. On approach, in stage I (tumor size < 5 cm) complete resection of tumor is enough and in stage II (gross tumor resection but residual microscopic disease) surgery followed by irradiation is the treatment of choice [6]. If the tumor is inoperable, radiotherapy can be done as palliative treatment [3].

This is a poorly-known tumor, but there have been some markers described that confers a poor prognosis to the tumor as the synaptophysin expression and a palpable tumor mass. Fascina expression has been described in many carcinomas and some sarcomas associated with aggressive behavior of tumors, especially in relation to metastatic capacity. The absence of the EWS-FLI1 translocation might portend an unfavorable prognosis [2].

pPNET tends to recur locally and to metastasize early to regional lymph nodes, lungs, liver, bone, and bone marrow within 2-3 years after surgery, with a resulting of very poor prognosis. Outcome depends upon the localization and staging of the tumor, age of the patient, histologic classification, extent of surgical resection and time to treatment.

1.
Ellinger J, Bastian PJ, Hauser S, Biermann K, Müller SC: Primitive neuroectodermal tumor: rare, highly aggressive differential diagnosis in urologic malignancies. Urology 2006;68:257-262.
2.
Gurung P, Attar K, Peters J: Primitive neuro-ectodermal tumor of the spermatic cord. Int J Urol 2010;17:679-680.
3.
Hari S, Jain TP, Thulkar S, Bakhshi S: Imaging features of peripheral primitive neuroectodermal tumours. Br J Radiol 2008;81:975- 983.
4.
Javery O, Krajewski K, O'Regan K, Kis B, Giardino A, Jagannathan J, Ramaiya NH: A to Z of extraskeletal Ewing sarcoma family of tumors in adults: imaging features of primary disease, metastatic patterns, and treatment responses. AJR Am J Roentgenol 2011; 197:W1015-1022.
5.
Tan Y, Zhang H, Ma GL, Xiao EH, Wang XC: Peripheral primitive neuroectodermal tumor: dynamic CT, MRI and clinicopathological characteristics-analysis of 36 cases and review of the literature. Oncotarget 2014;5: 12968-12977.
6.
Fontaine C, Schots R, Braeckman J, Goossens A, Soete G, De Grève J: Long-term survival in an adult metastatic renal peripheral primitive neuroectodermal tumor (PPNET) with multimodality treatment including high-dose chemotherapy. Ann Oncol 1997;8:691- 694.
7.
Khong PL, Chan GC, Shek TW, Tam PK, Chan FL: Imaging of peripheral PNET: common and uncommon locations. Clin Radiol 2002;57:272-277.
8.
Hoffer FA, Gianturco LE, Fletcher JA, Grier HE: Percutaneous biopsy of peripheral primitive neuroectodermal tumors and Ewing's sarcomas for cytogenetic analysis. AJR Am J Roentgenol 1994;162:1141-1142.
9.
Kim MS, Kim B, Park CS, Song SY, Lee EJ, Park NH, Kim HS, Kim SH, Cho KS: Radiologic findings of peripheral primitive neuroectodermal tumor arising in the retroperitoneum. AJR Am J Roentgenol 2006;186: 1125-1132.
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.